Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
Key facts
- Who runs it
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 80 people enrolled
- Started
- 15 Apr 2026
- Ended
- 14 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- vonoprazan-based triple therapy (VAL regimen)
- Esomeprazole-based triple therapy (EAL regimen)
- Record updated
- 26 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥ 18 years
- Dyspeptic patients with positive for both rapid urease test and stool antigen test
- Patients giving written informed consent
Who cannot take part
- Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study
- Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study
- Previous H. pylori eradication therapy
- Patients with regular intake of NSAIDs or steroids
- Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy
- Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months
- Gastric or duodenal ulcer with current or recent bleeding on endoscopy
- Significant upper or lower gastrointestinal bleeding within 4 weeks
- Known case of malignancy, including MALToma
- Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)
- History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and/or levofloxacin
- Subjects with abnormal laboratory test at the start of the screening period:
- creatinine > 2 mg/dl SGPT > 2 x Upper limit of normal
- Pregnant, lactating woman or intend to become pregnant within the study period
- On colchicine
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.
Read full original descriptionShow less
The main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.
Researchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.
Participants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.
Four weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.
Drug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.
Participants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.
The 2 groups in the trial
- Vonoprazan-based triple therapy (VAL)Treatment being tested
Participants in this arms will receive vonoprazan based levofloxacin containing triple therapy for 14 days
Treatment: vonoprazan-based triple therapy (VAL regimen)
- Esomeprazole-based triple therapy (EAL)Existing treatment, for comparison
Participants in this arms will receive esomeprazole based levofloxacin containing triple therapy for 14 days
Treatment: Esomeprazole-based triple therapy (EAL regimen)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial
- Record updated
- 26 October 2026